Payment overview · 2025
General Payments
$599.47
31 reported records · 16 companies
Healthcare provider profile · identity verified
Tam Pham Mclean
Allopathic & Osteopathic Physicians|Family Medicine · WILLOUGHBY, OH · NPI 1114260122
Verified facts
What the public records show
CMS Open Payments records show Tam Pham Mclean received $599.47 in general payments during 2025 across 31 reported records.
Astellas Pharma US Inc accounted for 21.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Mounjaro by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $130.25 | 21.7% | 6 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $69.23 | 11.6% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $56.49 | 9.4% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $56.08 | 9.3% | 3 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $47.07 | 7.8% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $35.01 | 5.8% | 2 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $32.11 | 5.4% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $28.91 | 4.8% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $22.47 | 3.8% | 1 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $22.12 | 3.7% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.00 | 3.5% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $16.94 | 2.8% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $16.94 | 2.8% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $16.27 | 2.7% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.00 | 2.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.58 | 2.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $599.47 | 31 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $130.25 | 6 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $69.23 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $56.49 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $56.08 | 3 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $47.07 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $35.01 | 2 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $32.11 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $28.91 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $22.47 | 1 | 2025 |
Source payment records
|
|||||
| NEXPLANON Normalized: nexplanon |
Drug | Organon LLC | $22.12 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $21.00 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $16.94 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $16.94 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $16.94 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $16.27 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $15.00 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $13.58 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $13.58 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
36 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 257 | 72 |
| Atorvastatin Calcium | Atorvastatin Calcium | 232 | 88 |
| Amlodipine Besylate | Amlodipine Besylate | 179 | 65 |
| Metoprolol Succinate | Metoprolol Succinate | 103 | 26 |
| Omeprazole | Omeprazole | 99 | 40 |
| Gabapentin | Gabapentin | 98 | 46 |
| Lisinopril | Lisinopril | 96 | 37 |
| Losartan Potassium | Losartan Potassium | 87 | 29 |
| Hydrochlorothiazide | Hydrochlorothiazide | 78 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 71 | 28 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 61 | 26 |
| Pantoprazole Sodium | Pantoprazole Sodium | 57 | 25 |
| Metformin Hcl | Metformin Hcl | 56 | 21 |
| Simvastatin | Simvastatin | 50 | 18 |
| Sertraline Hcl | Sertraline Hcl | 48 | 14 |
| Meloxicam | Meloxicam | 46 | 17 |
| Carvedilol | Carvedilol | 44 | 19 |
| Trazodone Hcl | Trazodone Hcl | 40 | 16 |
| Metformin Hcl Er | Metformin Hcl | 39 | 15 |
| Alprazolam | Alprazolam | 36 | suppressed |
| Synthroid | Levothyroxine Sodium | 36 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 34 | 18 |
| Atenolol | Atenolol | 33 | 11 |
| Tamsulosin Hcl | Tamsulosin Hcl | 33 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 32 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 31 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 30 | 12 |
| Montelukast Sodium | Montelukast Sodium | 30 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 28 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 28 | 11 |
| Ozempic | Semaglutide | 28 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 27 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 27 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 27 | suppressed |
| Rybelsus | Semaglutide | 26 | suppressed |
| Ezetimibe | Ezetimibe | 25 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 24 | 16 |
| Mounjaro | Tirzepatide | 24 | suppressed |
| Potassium Chloride | Potassium Chloride | 24 | suppressed |
| Jardiance | Empagliflozin | 23 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 23 | suppressed |
| Lovastatin | Lovastatin | 23 | suppressed |
| Furosemide | Furosemide | 22 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 20 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 20 | suppressed |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 19 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 18 | suppressed |
| Ibuprofen | Ibuprofen | 18 | 14 |
| Topiramate | Topiramate | 18 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 18 | suppressed |
| Allopurinol | Allopurinol | 17 | suppressed |
| Famotidine | Famotidine | 17 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 17 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Prednisone | Prednisone | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Bupropion Xl | Bupropion Hcl | 15 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 15 | suppressed |
| Januvia | Sitagliptin Phosphate | 15 | suppressed |
| Spironolactone | Spironolactone | 15 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 14 | suppressed |
| Eliquis | Apixaban | 14 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Methylprednisolone | Methylprednisolone | 14 | 14 |
| Nystatin | Nystatin | 14 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 13 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Glimepiride | Glimepiride | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | 12 |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Finasteride | Finasteride | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $599.47 · 31 records | Astellas Pharma US Inc | AIRSUPRA, Auvelity, CAPLYTA, Cologuard Collection Kit, Dexcom G6 Transmitter, FREESTYLE LIBRE 3, GVOKE HYPOPEN, JARDIANCE, Kerendia, Korlym, NEXPLANON, OTEZLA, QULIPTA, REPATHA, TRELEGY ELLIPTA, TZIELD, UBRELVY, Veozah | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error